Fentanyl Pharmacology and Clinical Implications

Primary Mechanism and Receptor Interaction

Fentanyl demonstrates weak activity at kappa-opioid receptors, in addition to its primary interaction with mu-opioid receptors, which are widely distributed in the brain, spinal cord, and other tissues throughout the body 1

Provides potent analgesia by modulating pain perception at multiple levels of the nervous system 1

May cause a small reduction in arterial blood pressure and heart rate in response to vagal stimulation, with relatively little direct effect on the cardiovascular system compared to other opioids 2

Fentanyl is highly lipid-soluble, which allows it to rapidly cross the blood-brain barrier and reach opioid receptors quickly, enabling multiple routes of administration including transdermal, transmucosal, buccal, intranasal, and parenteral delivery 2, 3, 4
The onset of action after intravenous administration is 1-2 minutes with a duration of effect of 30-60 minutes 2, 3
Fentanyl is approximately 80 times more potent than parenteral morphine due to its high receptor affinity and lipid solubility 5

Unlike morphine, fentanyl has no known active metabolites that accumulate in renal insufficiency, making it safer in patients with kidney disease 4
In large doses, fentanyl may induce chest-wall rigidity resulting from centrally mediated, generalized hypertonicity of skeletal muscle, which can make assisted ventilation difficult 2

Rapid-onset opioid formulations provide clinically observable analgesia within 10-15 minutes after administration, with superior temporal characteristics compared to oral morphine, in patients with breakthrough cancer pain 6, 7
These formulations have onset times of 10-15 minutes, compared to oral morphine which has an onset time of 20-30 minutes and a peak time of 60-90 minutes, in patients with cancer pain 6, 8

Transmucosal fentanyl formulations have a Grade I, Level A recommendation for unpredictable and rapid-onset breakthrough cancer pain in opioid-tolerant patients, according to the European Society for Medical Oncology 6, 7, 8
These formulations are indicated only for patients receiving oral morphine equivalents of at least 60 mg daily, and all available transmucosal fentanyl formulations demonstrate efficacy, with no evidence for superiority of any particular formulation, in patients with breakthrough cancer pain 6, 7

Dosing recommendations for transmucosal fentanyl share a low initial dose followed by titration to effective dose, regardless of formulation, in patients with breakthrough cancer pain 6, 8
Some evidence suggests initial doses proportionate to baseline opioid dose improve tolerability, though further confirmation is needed, in patients with cancer pain 6